Zafirlukast is an oral leukotriene receptor antagonist indicated for the prophylaxis and treatment of chronic asthma. Pulmonary function and symptom control are improved and the incidence of asthma exacerbations is reduced in patients with mild-to-moderate asthma treated with zafirlukast 20mg twice daily. As an oral medication, the drug may be particularly useful in patients with incorrect inhaler technique.
Pharyngitis and headache are the most frequently reported adverse effects associated with zafirlukast treatment. A very small number of cases of Churg-Strauss syndrome have been reported in patients who were being withdrawn from oral corticosteroid therapy while receiving treatment with zafirlukast.
More data are needed to establish the comparative efficacy of zafirlukast versus other medications available for the treatment of asthma.